Global Genetic Obesity Drug Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 102

Published Date: 16 May 2022

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Genetic Obesity Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Genetic Obesity Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospitals Pharmacy accounting for % of the Genetic Obesity Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Sibutramine segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Genetic Obesity Drug include Pfizer, Inc., Sanofi., Tonghua Dongbao Pharmaceutical Co., Ltd., Biocon., and Adocia, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
Genetic Obesity Drug market is split by Drug Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Drug Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Drug Type, covers
Sibutramine
Orlistat
Sympathomimetic Drugs
Receptors Antagonists
Others

Market segment by Application, can be divided into
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Market segment by players, this report covers
Pfizer, Inc.
Sanofi.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon.
Adocia
GlaxoSmithKline Plc.
Novo Nordisk A/S.
Oramed Pharmaceuticals, Inc
Wockhardt.
Eli Lilly and Company.
Merck & Co., Inc.
Julphar.
Bristol-Myers Squibb Company.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Genetic Obesity Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Genetic Obesity Drug, with revenue, gross margin and global market share of Genetic Obesity Drug from 2019 to 2022.
Chapter 3, the Genetic Obesity Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Drug Type and application, with revenue and growth rate by Drug Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Genetic Obesity Drug market forecast, by regions, drug type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Genetic Obesity Drug research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Genetic Obesity Drug
1.2 Classification of Genetic Obesity Drug by Drug Type
1.2.1 Overview: Global Genetic Obesity Drug Market Size by Drug Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Genetic Obesity Drug Revenue Market Share by Drug Type in 2021
1.2.3 Sibutramine
1.2.4 Orlistat
1.2.5 Sympathomimetic Drugs
1.2.6 Receptors Antagonists
1.2.7 Others
1.3 Global Genetic Obesity Drug Market by Application
1.3.1 Overview: Global Genetic Obesity Drug Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Global Genetic Obesity Drug Market Size & Forecast
1.5 Global Genetic Obesity Drug Market Size and Forecast by Region
1.5.1 Global Genetic Obesity Drug Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Genetic Obesity Drug Market Size by Region, (2017-2022)
1.5.3 North America Genetic Obesity Drug Market Size and Prospect (2017-2028)
1.5.4 Europe Genetic Obesity Drug Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Genetic Obesity Drug Market Size and Prospect (2017-2028)
1.5.6 South America Genetic Obesity Drug Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Genetic Obesity Drug Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Genetic Obesity Drug Market Drivers
1.6.2 Genetic Obesity Drug Market Restraints
1.6.3 Genetic Obesity Drug Trends Analysis

2 Company Profiles
2.1 Pfizer, Inc.
2.1.1 Pfizer, Inc. Details
2.1.2 Pfizer, Inc. Major Business
2.1.3 Pfizer, Inc. Genetic Obesity Drug Product and Solutions
2.1.4 Pfizer, Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Pfizer, Inc. Recent Developments and Future Plans
2.2 Sanofi.
2.2.1 Sanofi. Details
2.2.2 Sanofi. Major Business
2.2.3 Sanofi. Genetic Obesity Drug Product and Solutions
2.2.4 Sanofi. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Sanofi. Recent Developments and Future Plans
2.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
2.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Details
2.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Major Business
2.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product and Solutions
2.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.4 Biocon.
2.4.1 Biocon. Details
2.4.2 Biocon. Major Business
2.4.3 Biocon. Genetic Obesity Drug Product and Solutions
2.4.4 Biocon. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Biocon. Recent Developments and Future Plans
2.5 Adocia
2.5.1 Adocia Details
2.5.2 Adocia Major Business
2.5.3 Adocia Genetic Obesity Drug Product and Solutions
2.5.4 Adocia Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Adocia Recent Developments and Future Plans
2.6 GlaxoSmithKline Plc.
2.6.1 GlaxoSmithKline Plc. Details
2.6.2 GlaxoSmithKline Plc. Major Business
2.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Product and Solutions
2.6.4 GlaxoSmithKline Plc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 GlaxoSmithKline Plc. Recent Developments and Future Plans
2.7 Novo Nordisk A/S.
2.7.1 Novo Nordisk A/S. Details
2.7.2 Novo Nordisk A/S. Major Business
2.7.3 Novo Nordisk A/S. Genetic Obesity Drug Product and Solutions
2.7.4 Novo Nordisk A/S. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Novo Nordisk A/S. Recent Developments and Future Plans
2.8 Oramed Pharmaceuticals, Inc
2.8.1 Oramed Pharmaceuticals, Inc Details
2.8.2 Oramed Pharmaceuticals, Inc Major Business
2.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product and Solutions
2.8.4 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Oramed Pharmaceuticals, Inc Recent Developments and Future Plans
2.9 Wockhardt.
2.9.1 Wockhardt. Details
2.9.2 Wockhardt. Major Business
2.9.3 Wockhardt. Genetic Obesity Drug Product and Solutions
2.9.4 Wockhardt. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Wockhardt. Recent Developments and Future Plans
2.10 Eli Lilly and Company.
2.10.1 Eli Lilly and Company. Details
2.10.2 Eli Lilly and Company. Major Business
2.10.3 Eli Lilly and Company. Genetic Obesity Drug Product and Solutions
2.10.4 Eli Lilly and Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Eli Lilly and Company. Recent Developments and Future Plans
2.11 Merck & Co., Inc.
2.11.1 Merck & Co., Inc. Details
2.11.2 Merck & Co., Inc. Major Business
2.11.3 Merck & Co., Inc. Genetic Obesity Drug Product and Solutions
2.11.4 Merck & Co., Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Merck & Co., Inc. Recent Developments and Future Plans
2.12 Julphar.
2.12.1 Julphar. Details
2.12.2 Julphar. Major Business
2.12.3 Julphar. Genetic Obesity Drug Product and Solutions
2.12.4 Julphar. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Julphar. Recent Developments and Future Plans
2.13 Bristol-Myers Squibb Company.
2.13.1 Bristol-Myers Squibb Company. Details
2.13.2 Bristol-Myers Squibb Company. Major Business
2.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Product and Solutions
2.13.4 Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Bristol-Myers Squibb Company. Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Genetic Obesity Drug Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Genetic Obesity Drug Players Market Share in 2021
3.2.2 Top 10 Genetic Obesity Drug Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Genetic Obesity Drug Players Head Office, Products and Services Provided
3.4 Genetic Obesity Drug Mergers & Acquisitions
3.5 Genetic Obesity Drug New Entrants and Expansion Plans

4 Market Size Segment by Drug Type
4.1 Global Genetic Obesity Drug Revenue and Market Share by Drug Type (2017-2022)
4.2 Global Genetic Obesity Drug Market Forecast by Drug Type (2023-2028)

5 Market Size Segment by Application
5.1 Global Genetic Obesity Drug Revenue Market Share by Application (2017-2022)
5.2 Global Genetic Obesity Drug Market Forecast by Application (2023-2028)

6 North America by Country, by Drug Type, and by Application
6.1 North America Genetic Obesity Drug Revenue by Drug Type (2017-2028)
6.2 North America Genetic Obesity Drug Revenue by Application (2017-2028)
6.3 North America Genetic Obesity Drug Market Size by Country
6.3.1 North America Genetic Obesity Drug Revenue by Country (2017-2028)
6.3.2 United States Genetic Obesity Drug Market Size and Forecast (2017-2028)
6.3.3 Canada Genetic Obesity Drug Market Size and Forecast (2017-2028)
6.3.4 Mexico Genetic Obesity Drug Market Size and Forecast (2017-2028)

7 Europe by Country, by Drug Type, and by Application
7.1 Europe Genetic Obesity Drug Revenue by Drug Type (2017-2028)
7.2 Europe Genetic Obesity Drug Revenue by Application (2017-2028)
7.3 Europe Genetic Obesity Drug Market Size by Country
7.3.1 Europe Genetic Obesity Drug Revenue by Country (2017-2028)
7.3.2 Germany Genetic Obesity Drug Market Size and Forecast (2017-2028)
7.3.3 France Genetic Obesity Drug Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Genetic Obesity Drug Market Size and Forecast (2017-2028)
7.3.5 Russia Genetic Obesity Drug Market Size and Forecast (2017-2028)
7.3.6 Italy Genetic Obesity Drug Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Drug Type, and by Application
8.1 Asia-Pacific Genetic Obesity Drug Revenue by Drug Type (2017-2028)
8.2 Asia-Pacific Genetic Obesity Drug Revenue by Application (2017-2028)
8.3 Asia-Pacific Genetic Obesity Drug Market Size by Region
8.3.1 Asia-Pacific Genetic Obesity Drug Revenue by Region (2017-2028)
8.3.2 China Genetic Obesity Drug Market Size and Forecast (2017-2028)
8.3.3 Japan Genetic Obesity Drug Market Size and Forecast (2017-2028)
8.3.4 South Korea Genetic Obesity Drug Market Size and Forecast (2017-2028)
8.3.5 India Genetic Obesity Drug Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Genetic Obesity Drug Market Size and Forecast (2017-2028)
8.3.7 Australia Genetic Obesity Drug Market Size and Forecast (2017-2028)

9 South America by Country, by Drug Type, and by Application
9.1 South America Genetic Obesity Drug Revenue by Drug Type (2017-2028)
9.2 South America Genetic Obesity Drug Revenue by Application (2017-2028)
9.3 South America Genetic Obesity Drug Market Size by Country
9.3.1 South America Genetic Obesity Drug Revenue by Country (2017-2028)
9.3.2 Brazil Genetic Obesity Drug Market Size and Forecast (2017-2028)
9.3.3 Argentina Genetic Obesity Drug Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Drug Type, and by Application
10.1 Middle East & Africa Genetic Obesity Drug Revenue by Drug Type (2017-2028)
10.2 Middle East & Africa Genetic Obesity Drug Revenue by Application (2017-2028)
10.3 Middle East & Africa Genetic Obesity Drug Market Size by Country
10.3.1 Middle East & Africa Genetic Obesity Drug Revenue by Country (2017-2028)
10.3.2 Turkey Genetic Obesity Drug Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Genetic Obesity Drug Market Size and Forecast (2017-2028)
10.3.4 UAE Genetic Obesity Drug Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Genetic Obesity Drug Revenue by Drug Type, (USD Million), 2017 VS 2021 VS 2028
    Table 2. Global Genetic Obesity Drug Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
    Table 3. Global Market Genetic Obesity Drug Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
    Table 4. Global Genetic Obesity Drug Revenue (USD Million) by Region (2017-2022)
    Table 5. Global Genetic Obesity Drug Revenue Market Share by Region (2023-2028)
    Table 6. Pfizer, Inc. Corporate Information, Head Office, and Major Competitors
    Table 7. Pfizer, Inc. Major Business
    Table 8. Pfizer, Inc. Genetic Obesity Drug Product and Solutions
    Table 9. Pfizer, Inc. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 10. Sanofi. Corporate Information, Head Office, and Major Competitors
    Table 11. Sanofi. Major Business
    Table 12. Sanofi. Genetic Obesity Drug Product and Solutions
    Table 13. Sanofi. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 14. Tonghua Dongbao Pharmaceutical Co., Ltd. Corporate Information, Head Office, and Major Competitors
    Table 15. Tonghua Dongbao Pharmaceutical Co., Ltd. Major Business
    Table 16. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product and Solutions
    Table 17. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 18. Biocon. Corporate Information, Head Office, and Major Competitors
    Table 19. Biocon. Major Business
    Table 20. Biocon. Genetic Obesity Drug Product and Solutions
    Table 21. Biocon. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 22. Adocia Corporate Information, Head Office, and Major Competitors
    Table 23. Adocia Major Business
    Table 24. Adocia Genetic Obesity Drug Product and Solutions
    Table 25. Adocia Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 26. GlaxoSmithKline Plc. Corporate Information, Head Office, and Major Competitors
    Table 27. GlaxoSmithKline Plc. Major Business
    Table 28. GlaxoSmithKline Plc. Genetic Obesity Drug Product and Solutions
    Table 29. GlaxoSmithKline Plc. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 30. Novo Nordisk A/S. Corporate Information, Head Office, and Major Competitors
    Table 31. Novo Nordisk A/S. Major Business
    Table 32. Novo Nordisk A/S. Genetic Obesity Drug Product and Solutions
    Table 33. Novo Nordisk A/S. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 34. Oramed Pharmaceuticals, Inc Corporate Information, Head Office, and Major Competitors
    Table 35. Oramed Pharmaceuticals, Inc Major Business
    Table 36. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product and Solutions
    Table 37. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 38. Wockhardt. Corporate Information, Head Office, and Major Competitors
    Table 39. Wockhardt. Major Business
    Table 40. Wockhardt. Genetic Obesity Drug Product and Solutions
    Table 41. Wockhardt. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 42. Eli Lilly and Company. Corporate Information, Head Office, and Major Competitors
    Table 43. Eli Lilly and Company. Major Business
    Table 44. Eli Lilly and Company. Genetic Obesity Drug Product and Solutions
    Table 45. Eli Lilly and Company. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 46. Merck & Co., Inc. Corporate Information, Head Office, and Major Competitors
    Table 47. Merck & Co., Inc. Major Business
    Table 48. Merck & Co., Inc. Genetic Obesity Drug Product and Solutions
    Table 49. Merck & Co., Inc. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 50. Julphar. Corporate Information, Head Office, and Major Competitors
    Table 51. Julphar. Major Business
    Table 52. Julphar. Genetic Obesity Drug Product and Solutions
    Table 53. Julphar. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 54. Bristol-Myers Squibb Company. Corporate Information, Head Office, and Major Competitors
    Table 55. Bristol-Myers Squibb Company. Major Business
    Table 56. Bristol-Myers Squibb Company. Genetic Obesity Drug Product and Solutions
    Table 57. Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
    Table 58. Global Genetic Obesity Drug Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
    Table 59. Global Genetic Obesity Drug Revenue Share by Players (2019, 2020, 2021, and 2022)
    Table 60. Breakdown of Genetic Obesity Drug by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 61. Genetic Obesity Drug Players Head Office, Products and Services Provided
    Table 62. Genetic Obesity Drug Mergers & Acquisitions in the Past Five Years
    Table 63. Genetic Obesity Drug New Entrants and Expansion Plans
    Table 64. Global Genetic Obesity Drug Revenue (USD Million) by Drug Type (2017-2022)
    Table 65. Global Genetic Obesity Drug Revenue Share by Drug Type (2017-2022)
    Table 66. Global Genetic Obesity Drug Revenue Forecast by Drug Type (2023-2028)
    Table 67. Global Genetic Obesity Drug Revenue by Application (2017-2022)
    Table 68. Global Genetic Obesity Drug Revenue Forecast by Application (2023-2028)
    Table 69. North America Genetic Obesity Drug Revenue by Drug Type (2017-2022) & (USD Million)
    Table 70. North America Genetic Obesity Drug Revenue by Drug Type (2023-2028) & (USD Million)
    Table 71. North America Genetic Obesity Drug Revenue by Application (2017-2022) & (USD Million)
    Table 72. North America Genetic Obesity Drug Revenue by Application (2023-2028) & (USD Million)
    Table 73. North America Genetic Obesity Drug Revenue by Country (2017-2022) & (USD Million)
    Table 74. North America Genetic Obesity Drug Revenue by Country (2023-2028) & (USD Million)
    Table 75. Europe Genetic Obesity Drug Revenue by Drug Type (2017-2022) & (USD Million)
    Table 76. Europe Genetic Obesity Drug Revenue by Drug Type (2023-2028) & (USD Million)
    Table 77. Europe Genetic Obesity Drug Revenue by Application (2017-2022) & (USD Million)
    Table 78. Europe Genetic Obesity Drug Revenue by Application (2023-2028) & (USD Million)
    Table 79. Europe Genetic Obesity Drug Revenue by Country (2017-2022) & (USD Million)
    Table 80. Europe Genetic Obesity Drug Revenue by Country (2023-2028) & (USD Million)
    Table 81. Asia-Pacific Genetic Obesity Drug Revenue by Drug Type (2017-2022) & (USD Million)
    Table 82. Asia-Pacific Genetic Obesity Drug Revenue by Drug Type (2023-2028) & (USD Million)
    Table 83. Asia-Pacific Genetic Obesity Drug Revenue by Application (2017-2022) & (USD Million)
    Table 84. Asia-Pacific Genetic Obesity Drug Revenue by Application (2023-2028) & (USD Million)
    Table 85. Asia-Pacific Genetic Obesity Drug Revenue by Region (2017-2022) & (USD Million)
    Table 86. Asia-Pacific Genetic Obesity Drug Revenue by Region (2023-2028) & (USD Million)
    Table 87. South America Genetic Obesity Drug Revenue by Drug Type (2017-2022) & (USD Million)
    Table 88. South America Genetic Obesity Drug Revenue by Drug Type (2023-2028) & (USD Million)
    Table 89. South America Genetic Obesity Drug Revenue by Application (2017-2022) & (USD Million)
    Table 90. South America Genetic Obesity Drug Revenue by Application (2023-2028) & (USD Million)
    Table 91. South America Genetic Obesity Drug Revenue by Country (2017-2022) & (USD Million)
    Table 92. South America Genetic Obesity Drug Revenue by Country (2023-2028) & (USD Million)
    Table 93. Middle East & Africa Genetic Obesity Drug Revenue by Drug Type (2017-2022) & (USD Million)
    Table 94. Middle East & Africa Genetic Obesity Drug Revenue by Drug Type (2023-2028) & (USD Million)
    Table 95. Middle East & Africa Genetic Obesity Drug Revenue by Application (2017-2022) & (USD Million)
    Table 96. Middle East & Africa Genetic Obesity Drug Revenue by Application (2023-2028) & (USD Million)
    Table 97. Middle East & Africa Genetic Obesity Drug Revenue by Country (2017-2022) & (USD Million)
    Table 98. Middle East & Africa Genetic Obesity Drug Revenue by Country (2023-2028) & (USD Million)
List of Figures
    Figure 1. Genetic Obesity Drug Picture
    Figure 2. Global Genetic Obesity Drug Revenue Market Share by Drug Type in 2021
    Figure 3. Sibutramine
    Figure 4. Orlistat
    Figure 5. Sympathomimetic Drugs
    Figure 6. Receptors Antagonists
    Figure 7. Others
    Figure 8. Genetic Obesity Drug Revenue Market Share by Application in 2021
    Figure 9. Hospitals Pharmacy Picture
    Figure 10. Retail Pharmacy Picture
    Figure 11. Online Pharmacy Picture
    Figure 12. Others Picture
    Figure 13. Global Genetic Obesity Drug Market Size, (USD Million): 2017 VS 2021 VS 2028
    Figure 14. Global Genetic Obesity Drug Revenue and Forecast (2017-2028) & (USD Million)
    Figure 15. Global Genetic Obesity Drug Revenue Market Share by Region (2017-2028)
    Figure 16. Global Genetic Obesity Drug Revenue Market Share by Region in 2021
    Figure 17. North America Genetic Obesity Drug Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 18. Europe Genetic Obesity Drug Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 19. Asia-Pacific Genetic Obesity Drug Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 20. South America Genetic Obesity Drug Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 21. Middle East and Africa Genetic Obesity Drug Revenue (USD Million) and Growth Rate (2017-2028)
    Figure 22. Genetic Obesity Drug Market Drivers
    Figure 23. Genetic Obesity Drug Market Restraints
    Figure 24. Genetic Obesity Drug Market Trends
    Figure 25. Pfizer, Inc. Recent Developments and Future Plans
    Figure 26. Sanofi. Recent Developments and Future Plans
    Figure 27. Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Developments and Future Plans
    Figure 28. Biocon. Recent Developments and Future Plans
    Figure 29. Adocia Recent Developments and Future Plans
    Figure 30. GlaxoSmithKline Plc. Recent Developments and Future Plans
    Figure 31. Novo Nordisk A/S. Recent Developments and Future Plans
    Figure 32. Oramed Pharmaceuticals, Inc Recent Developments and Future Plans
    Figure 33. Wockhardt. Recent Developments and Future Plans
    Figure 34. Eli Lilly and Company. Recent Developments and Future Plans
    Figure 35. Merck & Co., Inc. Recent Developments and Future Plans
    Figure 36. Julphar. Recent Developments and Future Plans
    Figure 37. Bristol-Myers Squibb Company. Recent Developments and Future Plans
    Figure 38. Global Genetic Obesity Drug Revenue Share by Players in 2021
    Figure 39. Genetic Obesity Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
    Figure 40. Global Top 3 Players Genetic Obesity Drug Revenue Market Share in 2021
    Figure 41. Global Top 10 Players Genetic Obesity Drug Revenue Market Share in 2021
    Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
    Figure 43. Global Genetic Obesity Drug Revenue Share by Drug Type in 2021
    Figure 44. Global Genetic Obesity Drug Market Share Forecast by Drug Type (2023-2028)
    Figure 45. Global Genetic Obesity Drug Revenue Share by Application in 2021
    Figure 46. Global Genetic Obesity Drug Market Share Forecast by Application (2023-2028)
    Figure 47. North America Genetic Obesity Drug Sales Market Share by Drug Type (2017-2028)
    Figure 48. North America Genetic Obesity Drug Sales Market Share by Application (2017-2028)
    Figure 49. North America Genetic Obesity Drug Revenue Market Share by Country (2017-2028)
    Figure 50. United States Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 51. Canada Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 52. Mexico Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 53. Europe Genetic Obesity Drug Sales Market Share by Drug Type (2017-2028)
    Figure 54. Europe Genetic Obesity Drug Sales Market Share by Application (2017-2028)
    Figure 55. Europe Genetic Obesity Drug Revenue Market Share by Country (2017-2028)
    Figure 56. Germany Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 57. France Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 58. United Kingdom Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 59. Russia Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 60. Italy Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 61. Asia-Pacific Genetic Obesity Drug Sales Market Share by Drug Type (2017-2028)
    Figure 62. Asia-Pacific Genetic Obesity Drug Sales Market Share by Application (2017-2028)
    Figure 63. Asia-Pacific Genetic Obesity Drug Revenue Market Share by Region (2017-2028)
    Figure 64. China Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 65. Japan Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 66. South Korea Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 67. India Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 68. Southeast Asia Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 69. Australia Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 70. South America Genetic Obesity Drug Sales Market Share by Drug Type (2017-2028)
    Figure 71. South America Genetic Obesity Drug Sales Market Share by Application (2017-2028)
    Figure 72. South America Genetic Obesity Drug Revenue Market Share by Country (2017-2028)
    Figure 73. Brazil Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 74. Argentina Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 75. Middle East and Africa Genetic Obesity Drug Sales Market Share by Drug Type (2017-2028)
    Figure 76. Middle East and Africa Genetic Obesity Drug Sales Market Share by Application (2017-2028)
    Figure 77. Middle East and Africa Genetic Obesity Drug Revenue Market Share by Country (2017-2028)
    Figure 78. Turkey Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 79. Saudi Arabia Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 80. UAE Genetic Obesity Drug Revenue and Growth Rate (2017-2028) & (USD Million)
    Figure 81. Methodology
    Figure 82. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pfizer, Inc.
Sanofi.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon.
Adocia
GlaxoSmithKline Plc.
Novo Nordisk A/S.
Oramed Pharmaceuticals, Inc
Wockhardt.
Eli Lilly and Company.
Merck & Co., Inc.
Julphar.
Bristol-Myers Squibb Company.

Related Reports

Global Genetic Obesity Drug Supply, Demand and Key Producers, 2023-2029

Global Genetic Obesity Drug Supply, Demand and Key Producers, 2023-2029

date 02 Sep 2023

date Pharma & Healthcare

The global Genetic Obesity Drug market size is expected to reach $ 4186.4 million by 2029, rising at a market growth of 6.3% CAGR during the forecast period (2023-2029).

Global Genetic Obesity Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Genetic Obesity Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 02 Sep 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Genetic Obesity Drug market size was valued at USD 2726.7 million in 2022 and is forecast to a readjusted size of USD 4186.4 million by 2029 with a CAGR of 6.3% during review period.

Global Genetic Obesity Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Genetic Obesity Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 10 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Genetic Obesity Drug market size was valued at USD 2726.7 million in 2023 and is forecast to a readjusted size of USD 4186.4 million by 2030 with a CAGR of 6.3% during review period.

Product Tags

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>